Prestige Consumer Healthcare Inc.
PBH NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$47.80
KIRA · Stoqly’s AI analyst, in plain words
- Prestige Consumer Healthcare Inc. had $1.1B of revenue in fiscal 2026, down 4.3% on the year before. Over five years, revenue changed +2.9% a year on average.
- Its operating margin was 28.4%, down 1.2 pts: of every 100 in sales, about 28 is left after running the business.
- Prestige Consumer Healthcare Inc. made $190M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 13.0% a year.
- Free cash flow was $246M in fiscal 2026, 22.6% of revenue.
- Prestige Consumer Healthcare Inc. returned $156M to shareholders in fiscal 2026, 63% of free cash flow. The diluted share count fell 2.7%.
- Prestige Consumer Healthcare Inc. owes $951M more than it holds in cash, about 2.8 years of operating profit.
Market cap
$2.3B
P/E
13.4x
Revenue
$1.1B
Net income
$190M
Free cash flow
$246M
Operating margin
28.4%
Prestige Consumer Healthcare Inc. in 30 seconds · fiscal 2026
Are sales growing?
−4.3%
No. Sales fell 4.3% last year.
Does it make a profit?
17.5%
Yes. It keeps 17.5% of every sale as profit.
Does profit turn into cash?
22.6%
Yes. 22.6% of sales ends up as free cash.
Is debt under control?
2.8x
Keep an eye on it. Repaying its debt would take 2.8 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
13.4x
One share costs 13.4 times its yearly profit per share.
What Prestige Consumer Healthcare Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 14, 2026
- Legal name
- Prestige Consumer Healthcare Inc.
- CIK
- 0001295947
Prestige Consumer Healthcare Inc. · PBH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Revenue growth | 15.2% | 3.8% | −0.2% | 1.1% | −4.3% |
| Net interest income | −$64.3M | −$69.2M | −$67.2M | −$47.6M | −$42.3M |
| Gross margin | 57.1% | 55.4% | 55.5% | 55.8% | 54.7% |
| Operating margin | 30.4% | −2.0% | 30.4% | 29.6% | 28.4% |
| Net income | $205M | −$82.3M | $209M | $215M | $190M |
| Net margin | 18.9% | −7.3% | 18.6% | 18.9% | 17.5% |
| Diluted EPS | $4.04 | −$1.65 | $4.17 | $4.29 | $3.91 |
| Cash | |||||
| Cash from operations | $260M | $230M | $249M | $252M | $258M |
| Capital expenditure | $9.6M | $7.8M | $9.6M | $8.2M | $11.2M |
| Free cash flow | $250M | $222M | $239M | $243M | $246M |
| FCF margin | 23.0% | 19.7% | 21.3% | 21.4% | 22.6% |
| Share buybacks | $0.0M | $50.0M | $25.0M | $51.5M | $156M |
| Share count change | 0.5% | −1.9% | 0.6% | −0.2% | −2.7% |
| Debt and strength | |||||
| Cash and short-term investments | $27.2M | $58.5M | $46.5M | $97.9M | $63.9M |
| Debt incl. finance leases | $1.5B | $1.4B | $1.1B | $1.0B | $1.0B |
| Shareholders' equity | $1.6B | $1.4B | $1.7B | $1.8B | $1.9B |
| Net debt / EBITDA | 4.0x | 126.5x | 2.9x | 2.5x | 2.8x |
| Current ratio | 2.0x | 2.4x | 3.2x | 4.2x | 3.6x |
| Interest coverage | 5.1x | −5.1x | 65.9x | 187.1x | — |
| Returns and quality | |||||
| Return on capital | 8.5% | −0.6% | 9.5% | 9.3% | 8.1% |
| Return on equity | 14.0% | −5.4% | 13.5% | 12.3% | 10.2% |
| Piotroski F-score | 6 | 6 | 8 | 7 | 5 |
| Altman Z'' | 2.7 | 2.3 | 3.6 | 4.0 | 4.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.4M
2 insiders
Of sales under plans
27%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Prestige Consumer Healthcare Inc. · PBH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $47.80 a share, the company is worth $2.3B: 13.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001295947). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.